Next-generation proteasome inhibitor MLN9708 sensitizes breast cancer cells to doxorubicin-induced apoptosis
Wang, H (Wang, Hao); Yu, Y (Yu, Yang); Jiang, Z (Jiang, Zheng); Cao, WM (Cao, Wen-Ming); Wang, ZY (Wang, Zhenyu); Dou, J (Dou, Jun); Zhao, YL (Zhao, Yanling); Cui, YF (Cui, Yunfu); Zhang, H (Zhang, Hong)
2016
发表期刊SCIENTIFIC REPORTS
卷号6期号:5
摘要Doxorubicin (Dox), one of the most effective chemotherapy drug for cancer treatment, is limited by its severe side effects and chemoresistance. Dox induces DNA damage and leads to significant proteomic changes in the cancer cells, which makes the ubiquitin-proteasome system a potential target to enhance the efficacy of Dox therapy. The unsuccessful clinical trials of proteasome inhibitor PS-341 (bortezomib) in solid tumors led to the invention of MLN9708 (ixazomib), an orally bioavailable next-generation proteasome inhibitor with improved pharmacokinetic and pharmacodynamic features. In this preclinical study, we used eight human breast cancer cell lines, which represent the major molecular subtypes of breast cancer, to validate the cytotoxic effects of MLN9708, alone and in combination with Dox. We found that MLN9708 had cytotoxic effects, induced autophagy and MKP-1 expression, and enhanced Dox-induced apoptosis in these cell lines. MLN9708 also enhanced Dox-induced JNK and p38 phosphorylation and inhibited Dox-induced I kappa B alpha degradation. Our in vitro results suggest that MLN9708 has antitumor effects in breast cancer and can sensitize breast cancer cells to Dox treatment. This promising combination may be an effective and feasible therapeutic option for treating breast cancer and warrants clinical validation.
DOI10.1038/srep26456
收录类别SCI
WOS记录号WOS:000376364100001
引用统计
被引频次:11[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.xjipc.cas.cn/handle/365002/4659
专题省部共建新疆特有药用资源利用重点实验室
作者单位1.Harbin Med Univ, Affiliated Hosp 2, Dept Hepatopancreatobiliary Surg, Harbin 150086, Heilongjiang, Peoples R China
2.Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
3.Harbin Med Univ, Med Genet Lab, Harbin 150081, Heilongjiang, Peoples R China
4.Chinese Acad Med Sci, Peking Union Med Coll, Canc Hosp, Dept Colorectal Surg, Beijing 100021, Peoples R China
5.Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou 310022, Zhejiang, Peoples R China
6.Jilin Univ, Hosp 2, Dept Breast Surg, Changchun 130041, Jilin, Peoples R China
7.Chinese Acad Sci, Xinjiang Tech Inst Phys & Chem, Xinjiang Key Lab Plant Resources & Nat Prod Chem, Urumqi 830011, Xinjiang, Peoples R China
8.Univ Texas MD Anderson Canc Ctr, Dept Mol & Translat Pathol, Houston, TX 77030 USA
推荐引用方式
GB/T 7714
Wang, H ,Yu, Y ,Jiang, Z ,et al. Next-generation proteasome inhibitor MLN9708 sensitizes breast cancer cells to doxorubicin-induced apoptosis[J]. SCIENTIFIC REPORTS,2016,6(5).
APA Wang, H .,Yu, Y .,Jiang, Z .,Cao, WM .,Wang, ZY .,...&Zhang, H .(2016).Next-generation proteasome inhibitor MLN9708 sensitizes breast cancer cells to doxorubicin-induced apoptosis.SCIENTIFIC REPORTS,6(5).
MLA Wang, H ,et al."Next-generation proteasome inhibitor MLN9708 sensitizes breast cancer cells to doxorubicin-induced apoptosis".SCIENTIFIC REPORTS 6.5(2016).
条目包含的文件
文件名称/大小 文献类型 版本类型 开放类型 使用许可
Next-generation prot(2743KB)期刊论文作者接受稿开放获取CC BY-NC-SA浏览 请求全文
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wang, H (Wang, Hao)]的文章
[Yu, Y (Yu, Yang)]的文章
[Jiang, Z (Jiang, Zheng)]的文章
百度学术
百度学术中相似的文章
[Wang, H (Wang, Hao)]的文章
[Yu, Y (Yu, Yang)]的文章
[Jiang, Z (Jiang, Zheng)]的文章
必应学术
必应学术中相似的文章
[Wang, H (Wang, Hao)]的文章
[Yu, Y (Yu, Yang)]的文章
[Jiang, Z (Jiang, Zheng)]的文章
相关权益政策
暂无数据
收藏/分享
文件名: Next-generation proteasome inhibitor MLN9708 sensitizes breast cancer cells to doxorubicin-induced apoptosis.pdf
格式: Adobe PDF
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。